Psychosis News and Research

RSS

Psychosis means abnormal condition of the mind, and is a generic psychiatric term for a mental state often described as involving a "loss of contact with reality". People suffering from psychosis are said to be ''psychotic.''

Scientists, students share latest innovations in mental health at 13th Annual Research Half Day

Today, local scientists and students are sharing leading research in mental health. The 13th Annual Research Half Day, hosted by Lawson Health Research Institute and St. Joseph's Health Care London's Regional Mental Health Care (RMHC) London and St. Thomas, will present science that could change the course of patient care.

17 May 2012

Biogen Idec announces availability of two new AVONEX dosing innovations for MS

Biogen Idec announced that two new dosing innovations designed to help patients receiving once-a-week AVONEX (interferon beta-1a) for relapsing forms of multiple sclerosis (MS) are now available in U.S. pharmacies.

15 May 2012

Sunovion announces results from LATUDA open-label study for schizophrenia

Sunovion Pharmaceuticals Inc. today announced results from an open-label study that switched clinically stable, but symptomatic adult outpatients with schizophrenia from other antipsychotic agents to LATUDA.

10 May 2012

Study shows effects of psychotropic drug treatment on brain morphology

It is increasingly recognized that chronic psychotropic drug treatment may lead to structural remodeling of the brain. Indeed, clinical studies in humans present an intriguing picture: antipsychotics, used for the treatment of schizophrenia and psychosis, may contribute to cortical gray matter loss in patients, whereas lithium, used for the treatment of bipolar disorder and mania, may preserve gray matter in patients.

9 May 2012

ACADIA first quarter net loss increases to $6.2 million

ACADIA Pharmaceuticals Inc., a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders, today announced its unaudited financial results for the first quarter ended March 31, 2012.

9 May 2012

Otsuka announces results from aripiprazole Phase 3 trial on schizophrenia

Otsuka Pharmaceutical Co., Ltd. and H. Lundbeck A/S today announced results from a Phase 3 clinical trial evaluating the efficacy, safety and tolerability of once-monthly aripiprazole intramuscular (IM) depot formulation for the maintenance treatment of adults with schizophrenia.

8 May 2012

Positive results from Dainippon Sumitomo Pharma's LATUDA trials for bipolar I depression

Dainippon Sumitomo Pharma Co., Ltd. announced today results from two Phase 3 clinical trials designed to evaluate the efficacy and safety of LATUDA as adjunctive therapy and monotherapy, respectively, in patients with bipolar I depression (PREVAIL 1 and PREVAIL 2; PRogram to EValuate the Antidepressant Impact of Lurasidone).

7 May 2012

Elsevier, AAGP partner to publish American Journal of Geriatric Psychiatry

Elsevier, a world-leading provider of scientific, technical and medical information products and services, announces that it has entered into an agreement with the American Association for Geriatric Psychiatry (AAGP) to publish The American Journal of Geriatric Psychiatry (AJGP) beginning in January 2013.

3 May 2012

Parental history of psychosis linked with increased risk of epilepsy in offspring

Although the two disorders may seem dissimilar, epilepsy and psychosis are associated. Individuals with epilepsy are more likely to have schizophrenia, and a family history of epilepsy is a risk factor for psychosis. It is not known whether the converse is true, i.e., whether a family history of psychosis is a risk factor for epilepsy.

3 May 2012

Mylan receives final FDA approval for generic Zyprexa ANDA

Mylan Inc. today announced that its subsidiary Mylan Pharmaceuticals Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Olanzapine Tablets USP, 2.5 mg, 5 mg, 7.5 mg, 10 mg, 15 mg, and 20 mg.

25 Apr 2012

Viewpoints: Myths about women voters; Stopping fake drugs; Medicaid innovation not easy; The war over women

Women vote based on "women's issues," such as abortion rights and contraception. A recent poll of voters in swing states showed that women's top priorities are health care, gas prices, unemployment and the deficit -- in that order -- with "government policies toward contraception" coming in last

24 Apr 2012

Mylan receives FDA approval for generic Seroquel ANDA

29 Mar 2012

Synthetic marijuana use among teenagers raises concerns

According to reports three U.S. teenagers ended up in the emergency department with altered mental states and seriously elevated heart rates after smoking synthetic marijuana.

20 Mar 2012

FDA denies AstraZeneca Citizen Petitions on SEROQUEL labeling

AstraZeneca today announced that on March 7, 2012, the Food and Drug Administration denied Citizen Petitions requesting that the FDA withhold finally approving any generic quetiapine product with labeling that omits certain hyperglycemia warning language that the FDA required AstraZeneca to include in the labeling for SEROQUEL (quetiapine fumarate) tablets and SEROQUEL XR (quetiapine fumarate) extended-release tablets.

12 Mar 2012

Shire to commence two Vyvanse and Concerta Phase 4 comparison trials for ADHD

As part of its continued commitment to ADHD research, Shire plc, the global specialty biopharmaceutical company, today announced it is initiating two Phase 4 clinical trials to compare Vyvanse (lisdexamfetamine dimesylate) Capsules, (CII) to Concerta (methylphenidate HCl) Extended-Release Tablets.

7 Mar 2012

ACADIA, Allergan extend drug discovery collaboration

ACADIA Pharmaceuticals Inc., a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders, today announced that it has extended its drug discovery and development collaboration with Allergan, Inc..

5 Mar 2012

Helmholtz Association grant for research on diseases caused by protein misfolding

Professor Erich Wanker of the Max Delbr-ck Center for Molecular Medicine (MDC) Berlin-Buch and of the Excellence Cluster Neurocure is to receive EUR 675 000 in funding from the Helmholtz Association over the next two years. The grant shall be used to accelerate the search for active agents to treat diseases that are caused by protein misfolding. These include Alzheimer's and Parkinson's.

24 Feb 2012

Psychiatric disorders definitions to be revised

The definition of depression is proposed to be changed and now the diagnosis would characterize grieving as a disorder and greatly increase the number of people treated for it.

26 Jan 2012

Changes in endocannabinoid system may have important implications for psychiatric disorders

Changes in the endocannabinoid system may have important implications for psychiatric and addiction disorders. This brain system is responsible for making substances that have effects on brain function which resemble those of cannabis products, e.g., marijuana.

25 Jan 2012

SSRI use raises risk of fall among elderly with dementia: Study

A new study reveals that nursing home residents with dementia who use selective serotonin reuptake inhibitors (SSRIs) have an increased risk of having a fall that causes injury compared with those who do not use SSRIs. Additionally those using average doses have 3 times the risk compared with nonusers, the authors, led by Carolyn S. Sterke, from Erasmus University Medical Center, Rotterdam, the Netherlands, report. Authors write, “Even at low doses, SSRIs are associated with increased risk of an injurious fall in nursing home residents with dementia.”

22 Jan 2012